Answers are grounded in this paper and cite their sources.
RATIONALE: Prostate cancer treatment response may be automatically quantified using a molecular imaging analysis platform targeting prostate-specific membrane antigen (PSMA). METHODS: A retrospective analysis of patients with castration-sensitive prostate cancer who underwent PSMA-targeted molecular imaging prior to and 3 months or more after treatment was conducted. Disease burden was analyzed with aPROMISE, an artificial intelligence imaging platform that automatically quantifies PSMA-positive lesions. The calculated PSMA scores for prostate/bed, nodal, and osseous disease sites were compared with prostate-specific antigen (PSA) values. RESULTS: Of 30 eligible patients, the median decline in prostate/bed, nodal, and osseous disease PSMA scores were 100% (range 52-100%), 100% (range - 87-100%), and 100% (range - 21-100%), respectively. PSMA score decline was significantly associated with PSA decline. CONCLUSION: Changes in aPROMISE PSMA scores are associated with changes in PSA and may quantify treatment response.
No takes yet. Share an insight, caveat, or question.
Duriseti et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: